[Resistance to cytostatic agents in patients with refractory multiple myeloma and possible ways to control it].
At present several mechanisms responsible for the resistance of tumour cells to cytostatics are known. Most explored is the resistance conditioned by glycoprotein-P. Under laboratory conditions it proved possible to inhibit the resistance caused by glycoprotein-P by many substances which, however, on clinical administration have serious adverse side-effects. In practice verapamil was used, its effect was most marked in haematological malignant diseases. Side-effects of verapamil, however, do not permit to attain the necessary concentration. Obviously better results will be achieved by cyclosporin A which can attain a concentration in the organism which is necessary to inhibit glycoprotein-P without serious undesirable consequences. In the submitted paper the author reviews clinical studies concerned with possible inhibition of glycoprotein-P in patients with refractory myeloma.
Adam
Z
Z
II. interní klinika Fakultní nemocnice, Brno.
Vorlícek
J
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000502:physiology; D016572:Cyclosporine / Q000494:pharmacology; D004351:Drug Resistance; D006801:Humans; D008562:Membrane Glycoproteins / Q000502:physiology; D009101:Multiple Myeloma / Q000188:drug therapy*; D014700:Verapamil / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D016572:Cyclosporine; D014700:Verapamil
Rezistence na cytostatika a moznosti jejího ovlivnĕní u nemocných s refrakterním mnohocetným myelomem.